Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Flaherty

Showing results (221-230 of 580) with videos related to

Pageof 58
Sort By:
Radiographics : a Review Publication of the Radiological Society of North America, Inc|November 14, 2017
Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging FindingsGary X Wang, Vikram Kurra, Justin F Gainor, et al.
Oncotarget|April 19, 2014
Pathways and therapeutic targets in melanomaEmma Shtivelman, Michael Q A Davies, Patrick Hwu, et al.
Circulation|August 1, 1979
Comparison of myocardial protection with nifedipine and potassiumP G Magee, J T Flaherty, T J Bixler, et al.
Pigment Cell & Melanoma Research|October 3, 2018
A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF<sup>high</sup> /AXL<sup>low</sup> melanomaMichael P Smith, Sareena Rana, Jennifer Ferguson, et al.
Cancer Biology & Therapy|January 26, 2008
Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinomaKeith T Flaherty, Mark A Rosen, Daniel F Heitjan, et al.
Circulation|August 1, 1978
Effect of potassium cardioplegia on myocardial ischemia and post arrest ventricular functionH V Schaff, R Dombroff, J T Flaherty, et al.
Life Science Alliance|August 29, 2022
Proteasomal down-regulation of the proapoptotic MST2 pathway contributes to BRAF inhibitor resistance in melanomaDavid Romano, Lucía García-Gutiérrez, Nourhan Aboud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2016
Parallel In Vivo Assessment of Drug Phenotypes at Various Time Points during Systemic BRAF Inhibition Reveals Tumor Adaptation and Altered Treatment VulnerabilitiesOliver Jonas, Madeleine J Oudin, Tatsiana Kosciuk, et al.
The Journal of Organic Chemistry|December 20, 2003
Formal total synthesis of (+)-salicylihalamides A and B: a combined chiral pool and RCM strategyKyoungLang Yang, Burchelle Blackman, Wibke Diederich, et al.
Chest|October 1, 1981
Combined administration of nitroglycerin and propranolol to patients with acute myocardial infarctionP C Come, J T Flaherty, L C Becker, et al.
Pageof 58

Showing results (221-230 of 580) with videos related to

Sort By:
Pageof 58
Radiographics : a Review Publication of the Radiological Society of North America, Inc|November 14, 2017
Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging FindingsGary X Wang, Vikram Kurra, Justin F Gainor, et al.
Oncotarget|April 19, 2014
Pathways and therapeutic targets in melanomaEmma Shtivelman, Michael Q A Davies, Patrick Hwu, et al.
Circulation|August 1, 1979
Comparison of myocardial protection with nifedipine and potassiumP G Magee, J T Flaherty, T J Bixler, et al.
Pigment Cell & Melanoma Research|October 3, 2018
A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF<sup>high</sup> /AXL<sup>low</sup> melanomaMichael P Smith, Sareena Rana, Jennifer Ferguson, et al.
Cancer Biology & Therapy|January 26, 2008
Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinomaKeith T Flaherty, Mark A Rosen, Daniel F Heitjan, et al.
Circulation|August 1, 1978
Effect of potassium cardioplegia on myocardial ischemia and post arrest ventricular functionH V Schaff, R Dombroff, J T Flaherty, et al.
Life Science Alliance|August 29, 2022
Proteasomal down-regulation of the proapoptotic MST2 pathway contributes to BRAF inhibitor resistance in melanomaDavid Romano, Lucía García-Gutiérrez, Nourhan Aboud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2016
Parallel In Vivo Assessment of Drug Phenotypes at Various Time Points during Systemic BRAF Inhibition Reveals Tumor Adaptation and Altered Treatment VulnerabilitiesOliver Jonas, Madeleine J Oudin, Tatsiana Kosciuk, et al.
The Journal of Organic Chemistry|December 20, 2003
Formal total synthesis of (+)-salicylihalamides A and B: a combined chiral pool and RCM strategyKyoungLang Yang, Burchelle Blackman, Wibke Diederich, et al.
Chest|October 1, 1981
Combined administration of nitroglycerin and propranolol to patients with acute myocardial infarctionP C Come, J T Flaherty, L C Becker, et al.
Pageof 58